A new publication referencing cerebrolysin appeared on July 29, 2026. The paper, titled "Research-Evidence-Practice Gaps in Post-stroke Neuro-recovery Pharmacological Therapies in Asia," was published in Cerebrovascular Diseases Extra.
Cerebrolysin remains classified as an unapproved research compound. The publication is listed under PubMed ID 42525569 and is available for review through the journal's public listing.
This brief reports only that the publication exists and where it appeared. No findings, conclusions, or efficacy data from the paper are described here, as none were provided in the source event.
Readers interested in the broader context of cerebrolysin, including its regulatory status and research history, can consult the compound overview for further background.